PLK1 and lung carcinoma: Further corroborating the antagonistic role of autophagy, the clinically approved autophagy inhibitor chloroquine (Mauthe et al, 2018) potently enhances the cytotoxicity of FGFR1/PLK1 inhibitors in KRAS‐mutant lung cancer cells in vitro and in vivo.